Company
Pheontx
Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers
Also known as Pheon Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- pheontx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat difficult-to-treat solid tumors.
Funding snapshot
- Total raised
- $120MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $120M2024-05-21
Funding rounds
- Series B
- $120M2024-05-21, Company stated
Loading relationship preview